Vitamin D-neutralizing CYP24A1 expression, oncogenic mutation states and histological findings of human papillary thyroid cancer

Journal of Endocrinological Investigation

Volumn 38, Issue 3, 2015, Pages 313-321

  Balla, B ^a   Tobias B ^a   Kosa J P ^a   Podani, J ^b   Horvath P ^a   Nagy, Z ^a   Horanyi J ^a   Jaray B ^a   Szekely E ^a   Krenacs L ^c   Arvai K ^a   Dank, M ^a   Putz, Z ^a   Szabo B ^a   Szili, B ^a   Valkusz, Z ^d   Vasas, B ^d   Gyori, G ^a   Lakatos, P ^a   Takacs I ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c Laboratory of Tumor Pathology and Molecular Diagnostics   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

Author keywords

CYP24A1; Gene expression; Multivariate data analysis; Papillary thyroid carcinoma; Vitamin D

Indexed keywords

1 ALPHA HYDROXYLASE; COLECALCIFEROL 24 HYDROXYLASE; HYDROLASE; MESSENGER RNA; UNCLASSIFIED DRUG; B RAF KINASE; CALCIDIOL 1 MONOOXYGENASE; RAS PROTEIN;

1 ALPHA HYDROXYLASE GENE; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLECALCIFEROL 24 HYDROXYLASE GENE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; ONCOGENE; ONCOGENE BRAF; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PAPILLARY THYROID CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CANCER; TUMOR INVASION; TUMOR VOLUME; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR; VERY ELDERLY; YOUNG ADULT;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; THYROID NEOPLASMS; VITAMIN D3 24-HYDROXYLASE; YOUNG ADULT;

EID: 84924363109     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0165-7     Document Type: Article

References (31)

1. Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, Lichtenstein A, Patel K, Raman G, Tatsioni A, Terasawa T, Trikalinos TA (2009) Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess 183:1-420
2. Krishnan AV, Trump DL, Johnson CS, Feldman D (2010) The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin N Am 39(2):401-418
3. Kriebitzsch C, Verlinden L, Eelen G, Tan BK, Van Camp M, Bouillon R, Verstuyf A (2009) The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells - a microarray approach. Anticancer Res 29(9):3471-3483
4. Horvath HC, Lakatos P, Kosa JP, Bacsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G, Kallay E (2010) The candidate oncogene CYP24A1: a potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 58(3):277-285
5. Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J (2003) Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 164:239-246
6. Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M, Inoue H, Mori M (2004) Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol 15(2):236-241
7. Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM, Chuang SS, Nichols M, El-Hefnawy T, Hershberger PA (2006) CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 119(8):1819-1828
8. Horvath E, Lakatos P, Balla B, Kosa JP, Tobias B, Jozilan H, Borka K, Horvath HC, Kovalszky I, Szalay F (2012) Marked increase of CYP24A1 mRNA level in hepatocellular carcinoma cell lines following vitamin D administration. Anticancer Res 32(11):4791-4796
9. Zhang Q, Kanterewicz B, Buch S, Petkovich M, Parise R, Beumer J, Lin Y, Diergaarde B, Hershberger PA (2012) CYP24 inhibition preserves 1alpha,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Mol Cell Endocrinol 355(1):153-161
10. Kosa JP, Horvath P, Wolfling J, Kovacs D, Balla B, Matyus P, Horvath E, Speer G, Takacs I, Nagy Z, Horvath H, Lakatos P (2013) CYP24A1 inhibition facilitates the anti-tumor effect of vitamin D3 on colorectal cancer cells. World J Gastroenterol 19(17):2621-2628
11. Luo W, Yu WD, Ma Y, Chernov M, Trump DL, Johnson CS (2013) Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. Cancer Res 73(7):2289-2297
12. Sharma V, Fretwell D, Crees Z, Kerege A, Klopper JP (2010) Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism. Thyroid 20(10):1103-1111
13. Laney N, Meza J, Lyden E, Erickson J, Treude K, Goldner W (2010) The prevalence of vitamin D deficiency is similar between thyroid nodule and thyroid cancer patients. Int J Endocrinol 2010:805716
14. Stepien T, Krupinski R, Sopinski J, Kuzdak K, Komorowski J, Lawnicka H, Stepien H (2010) Decreased 1-25 dihydroxyvitamin D3 concentration in peripheral blood serum of patients with thyroid cancer. Arch Med Res 41(3):190-194
15. Clinckspoor I, Hauben E, Verlinden L, Van den Bruel A, Vanwalleghem L, Vander Poorten V, Delaere P, Mathieu C, Verstuyf A, Decallonne B (2012) Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J Histochem Cytochem 60(7):502-511
16. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30(2):216-222
17. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63(7):1454-1457
18. Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28(7):742-762
19. Paulson L, Shindo M, Schuff K, Corless C (2012) The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 138(1):44-49
20. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P (2010) Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95(9):4197-4205
21. Nikiforov YE, Nikiforova MN (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7(10):569-580
22. Balla B, Kosa JP, Tobias B, Halaszlaki C, Takacs I, Horvath H, Speer G, Nagy Z, Horanyi J, Jaray B, Szekely E, Lakatos P (2011) Marked increase in CYP24A1 gene expression in human papillary thyroid cancer. Thyroid 21(4):459-460
23. Podani J (2000) Introduction to the exploration of multivariate biological data. Backhuys, Leiden
24. Jolliffe I (1986) Principal component analysis. Springer, New York
25. Podani J (2001) SYN-TAX 2000. User's Manual, Scientia
26. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013:965212
27. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM (2007) Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype - papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol 18(1):1-7
28. Clinckspoor I, Verlinden L, Mathieu C, Bouillon R, Verstuyf A, Decallonne B (2013) Vitamin D in thyroid tumorigenesis and development. Prog Histochem Cytochem 48(2):65-98
29. Carpi A, Mechanick JI, Saussez S, Nicolini A (2010) Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications. J Cell Physiol 224(3):612-619
30. Khadzkou K, Buchwald P, Westin G, Dralle H, Akerstrom G, Hellman P (2006) 25-hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem 54(3):355-361
31. McLeod DS, Sawka AM, Cooper DS (2013) Controversies in primary treatment of low-risk papillary thyroid cancer. Lancet 381(9871):1046-1057